Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: A prospective study

被引:36
作者
Mazziotti, G
Sorvillo, F
Stornaiuolo, G
Rotondi, M
Morisco, F
Ruberto, M
Cioffi, M
Amato, G
Caporaso, N
Gaeta, GB
Carella, C
机构
[1] Univ Naples 2, Dept Clin & Expt Med F Magrassi, Naples, Italy
[2] Univ Naples 2, Dept Infect Dis, Naples, Italy
[3] Univ Naples 2, Dept Gen Pathol, Naples, Italy
[4] Univ Naples Federico II, Dept Food Sci, Naples, Italy
关键词
thyroid autoimmunity; thyroid dysfunction; interferon-alfa treatment; interferon consensus treatment; ribavirin; chronic hepatitis C;
D O I
10.1007/BF03345087
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In this prospective study we performed repeated evaluations of thyroid status in patients undergoing treatment with different preparations of recombinant interferons (IFNs), in order to identify early markers of thyroid dysfunction. Moreover, we aimed to investigate whether the development of thyroid dysfunction was related to the appearance of thyroid autoimmunity. Our study included 51 consecutive patients without pre-existing thyroid disease, admitted to our hospital for Hepatitis C virus (HCV)related chronic hepatitis. Thirty-six patients (Gr. A) were treated with IFN-alpha 2b plus ribavirin (RIBA), whereas 15 patients (Gr. B) underwent treatment with IFN-alphacon-1 (CIFN) plus RIBA. Thyroid autoimmunity and function were prospectively evaluated before, every month during treatment and for 6 months after IFN withdrawal. At study entry, all patients were euthyroid and negative for thyroid autoantibodies. In Gr. A, 10 patients developed thyroid autoimmunity after a median period of 3 months (range: 1-6) treatment with IFN-alpha+RIBA. At the time of appearance of thyroid autoantibodies, 4 patients developed destructive thyrotoxicosis (overt in one case, subclinical in 3 cases), while other 4 patients showed a high reduction of serum TSH levels (median decrease: -75.7%, range: -61.9- -84.2), which reached the low values of normal range. After a median period of 2 months (range: 1-3) from these biochemical abnormalities, 6 patients continuing antiviral treatment developed hypothyroidism (overt in 3 cases and subclinical in the other 3). In Gr. B, 5 patients developed thyroid autoimmunity after a median period of 3 months (range: 2-10) of treatment with CIFN+RIBA. Soon after the appearance of thyroid autoantibodies, all patients developed an overt thyrotoxicosis (with hyperthyroidism in 2 cases). Antiviral treatment was discontinued in all 5 cases. Thereafter, thyroid function recovered spontaneously without significant modifications of serum TGAb and TIPOAb levels until the end of the study. in conclusion our prospective study demonstrated that: 1) the appearance of thyroid autoantibodies during treatment with IFN was accompanied in most cases by the occurrence of a destructive process in the thyroid gland; 2) The clinical expression of destructive thyroiditis was more evident in patients treated with CIFN than that in patients treated with IFN; 3) The thyroid clinical outcome of these patients was strictly correlated to the continuation of cytokine treatment. (C) 2002, Editrice Kurtis.
引用
收藏
页码:624 / 630
页数:7
相关论文
共 32 条
[1]   The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon [J].
Blatt, LM ;
Davis, JM ;
Klein, SB ;
Taylor, MW .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1996, 16 (07) :489-499
[2]   THYROID AUTOIMMUNITY IN PATIENTS ON LONG-TERM THERAPY WITH LEUKOCYTE-DERIVED INTERFERON [J].
BURMAN, P ;
TOTTERMAN, TH ;
OBERG, K ;
KARLSSON, FA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1986, 63 (05) :1086-1090
[3]   LONGITUDINAL-STUDY OF ANTIBODIES AGAINST THYROID IN PATIENTS UNDERGOING INTERFERON-ALPHA THERAPY FOR HCV CHRONIC HEPATITIS [J].
CARELLA, C ;
AMATO, G ;
BIONDI, B ;
ROTONDI, M ;
MORISCO, F ;
TUCCILLO, C ;
CHIUCHIOLO, N ;
SIGNORIELLO, G ;
CAPORASO, N ;
LOMBARDI, G .
HORMONE RESEARCH, 1995, 44 (03) :110-114
[4]   The addition of ribavirin to interferon-α therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism [J].
Carella, C ;
Mazziotti, G ;
Morisco, F ;
Rotondi, M ;
Cioffi, M ;
Tuccillo, C ;
Sorvillo, F ;
Caporaso, N ;
Amato, G .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2002, 146 (06) :743-749
[5]   Long-term outcome of interferon-α-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment [J].
Carella, C ;
Mazziotti, G ;
Morisco, F ;
Manganella, G ;
Rotondi, M ;
Tuccillo, C ;
Sorvillo, F ;
Caporaso, N ;
Amato, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (05) :1925-1929
[6]   Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy [J].
Custro, N ;
Montalto, G ;
Scafidi, V ;
Soresi, M ;
Gallo, S ;
Tripi, S ;
Notarbartolo, A .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1997, 20 (07) :374-380
[7]  
DOUGLAS TF, 1996, SCIENCE, V272, P50
[8]  
FENTIMAN IS, 1985, LANCET, V1, P1166
[9]  
IMAGAWA A, 1995, J CLIN ENDOCR METAB, V80, P922, DOI 10.1210/jcem.80.3.7883851
[10]   Clinical significance of measurements of antithyroid antibodies in the diagnosis of Hashimoto's thyroiditis: Comparison with histological findings [J].
Kasagi, K ;
Kousaka, T ;
Higuchi, K ;
Iida, Y ;
Misaki, T ;
Alam, MS ;
Miyamoto, S ;
Yamabe, H ;
Konishi, J .
THYROID, 1996, 6 (05) :445-450